The CDTI SICC Innvierte of investing in Innovation ARTHEx Biotech, together with Invivo Ventures, F.C.R. and Columbus Life Sciences Fund III, F.C.R., to develop a new treatment of RNA for myotonic dystrophy

ARTHEx Biotech is a biotechnology company valenciana in clinical phase focused on the development of medicines from rna aimed for rare genetic neuromuscular disorders. Its major programme, ATX-01, is located in clinical evaluation for myotonic dystrophy type 1 (DM1) in the trial ArthemiR ™. The test ArthemiRTM is a comprehensive study I-IIa phase double-blind, placebo-controlled, single-dose upward and multiple participants with classical DM1. Its main objective is to determine the safety and tolerability of ATX-01 in participants with DM1. ARTHEx also investigate the commitment of muscle level through biomarkers. The evaluation criteria include clinical test measures related to muscle function, the results informed patients and the actions of the impact on the quality of life.
On this basis, ARTHEx Biotech is advancing a portfolio of therapies of RNA for other areas with high medical need not covered in muscular diseases of the central nervous system.

The CDTI Innovation, through Innvierte, has closed an operation of investment in this endeavour with Invivo Ventures, RCF and Columbus Life Sciences Fund III, RCF with an amount of investment of €4.132.000. Thanks to this participation, the CDTI Innovation contributes to the development of new treatments based on microARN inhibitors to myotonic dystrophy (neuromuscular disorder rare).

Invivo Ventures, F.C.R.

Fondo gestionado por INVIVO PARTNERS, S.G.E.I.C, S.A., firma de capital riesgo especializada en empresas de salud en etapas tempranas.
His team combines scientific, technical and financial shock for investment and foster the growth in the health sector, especially in biotechnology companies that develop innovative medicines, with a particular interest in advanced therapies and synthetic biology.

Columbus Life Sciences, F.C.R. Fund III

Columbus Venture Partners is a european risk capital in biotechnology and health sciences. With a model of differential treatment and an investment consolidated record with regard to promoting industrial platforms of advanced therapies, Columbus participates actively in the creation and growth of more than 80 per cent of their portfolio companies.

Innvierte

Innvierte is an initiative aimed at promoting the entrepreneurial innovation through support to the risk capital investment in technology-based enterprises or innovative programme. This is done through the collective investment type closed Innvierte Sustainable Economy SICC S.M.E., S.A., self-managed and under the supervision of the national Values and that the CDTI Innovation is a shareholder Only.

To date, the CDTI innovation has committed 2.847 M €in 63 investment vehicles that have invested in more than 632 companies, and through its joint investment line directly committed an amount of 726 M €in 191 companies.

Innvierte fits into the strategy for science, technology and innovation 2021-2027, adopted by decision of the council of ministers, in september. This 2020 Strategy contains goals, the reforms and measures to be taken throughout the area of r + D + i in order to boost their growth and impact, and is one of the pillars on which the design of the government's policy in r + D + i for the coming years.

CDTI Innovation

The centre for technological development and innovation, CDTI E.P.E. is the agency for innovation of the ministry of science, innovation and universities, whose goal is the promotion of technological innovation in business. The CDTI mission is to ensure that the business fabric english generates and transform knowledge into growth científico-técnico globally competitive, sustainable and inclusive. By 2024, within the framework of a new strategic plan, the CDTI provided more than $2.3 billion euros of support for business startups and spain.

More information:

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/cdti/
X:https :// x.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial

ARTHEx Biotech:
Website:https :// www.arthexbiotech.com/
In LinkedIn:https :// www.linkedin.com/company/arthex-pharma/
X:https :// x.com/Arthexbiotech

INVIVO PARTNERS, S.G.E.I.C, S.A:
Website:https :// invivo.partners/
In LinkedIn:https :// www.linkedin.com/company/invivopartners/
X:https :// x.com/InvivoPartners

Columbus Venture Partners:
Website:www.columbusvp.com
In LinkedIn:https :// www.linkedin.com/company/columbus-venture-partners/